Reported 26 days ago
Merck & Co. reported better-than-expected third-quarter earnings, but the company faces ongoing challenges with declining Gardasil sales in China, which are projected to persist into 2025. The sales of Gardasil decreased by 11% to $2.31 billion, missing analyst forecasts, due to low demand and inventory adjustments linked to anti-corruption measures affecting promotional activities. Despite the setback, Merck's overall sales grew, bolstered by a strong performance from its cancer treatment Keytruda.
Source: YAHOO